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Abstract
Background: A common method for presenting and studying biological interaction networks is
visualization. Software tools can enhance our ability to explore network visualizations and improve
our understanding of biological systems, particularly when these tools offer analysis capabilities.
However, most published network visualizations are static representations that do not support
user interaction.
Results: JNets was designed as a network visualization tool that incorporates annotation to
explore the underlying features of interaction networks. The software is available as an application
and a configurable applet that can provide a flexible and dynamic online interface to many types of
network data. As a case study, we use JNets to investigate approved drug targets present within
the HIV-1 Human protein interaction network. Our software highlights the intricate influence that
HIV-1 has on the host immune response.
Conclusion: JNets is a software tool that allows interaction networks to be visualized and studied
remotely, from within a standard web page. Therefore, using this free software, network data can
be presented in an enhanced, interactive format. More information about JNets is available at http:/
/www.manchester.ac.uk/bioinformatics/jnets.
Background
Interaction networks can be studied to gain a greater
understanding of the biological system that they represent
[1-4]. A common method for studying PPI networks is
through visualization, typically by representing a network
as a 'ball-and-stick' graph. Interactive visualizations can
enhance our understanding of networks and allow new
patterns and trends to be discerned [5], particularly when
these tools offer network analysis capabilities. However,
most published PPI network visualizations are static rep-
resentations that do not permit the user to view associated
annotation let alone integrate and analyze other biologi-
cal information in a useful manner.
The development of JNets was motivated by the need for
an online, interactive protein-protein interaction (PPI)
network viewer for the HIV-1, Human Protein Interaction
Database (HHPID) [6,7]. HHPID is a valuable resource
for the study of HIV-1 infection. HHPID data is manually
curated and in addition to the pairs of interacting HIV and
human genes, contains details of the interaction type (e.g.,
'phosphorylates' or 'complexes with'). Currently, many
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facilitate both interaction and analysis for example [8-13].
However, a flexible tool is required that can be deployed
from a website as an applet, that combines network visu-
alization and manipulation capabilities with analysis
methods focused on biological annotation (such as the
HHPID interaction type). This tool will aid in understand-
ing the mechanism of infection and the host-viral interac-
tions involved in the HIV-1 life cycle but will also be
useful for a wide range of network-related projects, bio-
logical or otherwise.
JNets is available as a stand-alone application and a web-
deployable applet and is applicable to any type of biolog-
ical or non-biological network data. Analysis in JNets is
achieved by overlaying node and edge annotation on to
the network. Groups of nodes and edges can be created by
filtering accompanying annotation, and properties of
groups can be explored, in terms of annotation, both vis-
ually and statistically. In addition, JNets is configureable
to allow web-deployed visualizations to be customized by
a vendor. Specifically, preset network visualizations can
be defined and the JNets user interface altered. Further-
more, JNets is free and platform independent.
Implementation
JNets is available in two forms: a stand-alone application
and a web-deployable applet. The latter has some features
disabled (such as the 'File menu') due to the security
requirements of Java applets. Certain advantageous fea-
tures in JNets were inherited from InterView [12], the soft-
ware on which JNets is based. These include the animated
spring layout, a container layout [12], interactive 'clicka-
ble' nodes and the facility to export network visualizations
in PDF and PNG formats. In addition, the Java libraries
responsible for graph layout, network rendering and the
legend panel also come from InterView. InterView uses
libraries from the TouchGraph package. These drive the
interactive network display in JNets. A diagrammatic sum-
mary that shows the organization of JNets is given in fig-
ure 1. JNets is available from http://
www.manchester.ac.uk/bioinformatics/jnets, where an
applet can be launched to visualize and browse the
HHPID network. Also available at this site is a download
package, including source code, documentation and
example data files.
Results
The following sub-sections describe the main features of
JNets in detail. Where appropriate, examples are given
Diagrammatic representation of the the JNets systemFigure 1
Diagrammatic representation of the the JNets system. This diagram describes the conceptual flow of information 
through the software.Page 2 of 14
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interface is described in figure 2.
Input files
JNets requires a main input file in Extensible Graph
Markup and Modeling Language (XGMML) format. This
XML format was chosen because it is designed to record
network structures and includes support for node and
edge annotation. To aid the creation of JNets-compatible
XGMML files, a tool for converting tab-delimited data is
provided in the JNets application. These input XGMML
files hold three types of information: (1) data that are
essential to the network structure, for example, node and
edge identifiers, node and edge names, edge directionality
and edge source-node and target-node identifiers. These
data are sent directly to components from InterView to
create and visualize the network. (2) Optional attributes
of the network display, such as x and y coordinates for
nodes to enable predefined layouts, initial node and edge
groupings and whether node labels are displayed on star-
tup. (3) Annotation, i.e., any additional data attributed to
a node or edge.
Element Annotation
In JNets, nodes and edges can be given any number of dif-
ferent annotations, these annotations can be used for net-
work analysis. Many other network visualization tools
offer annotation of graph elements, however, these are
often linked to specific, predetermined biological
resources. For example VisAnt integrates information
from the GO and KEGG databases [14]. For maximum
flexibility and ease of use, annotation in JNets is entirely
determined by the user. These annotations fall in to two
classes, either single or multiple. Single annotations are
those where only one value can be attributed to an ele-
ment. For example, nodes, representing proteins in
HHPID, could be annotated with a source organism taxo-
nomic identifier. Only one such value will be attributed to
each protein, either human or HIV-1. Therefore, taxo-
nomic identifier could be defined using a single annota-
tion. Multiple annotations are those where a single
element may have multiple values for one annotation. For
example, in HHPID every PPI is attributed with a list of
PubMed article identifiers that report the interaction. As
this can be one or multiple articles, PubMed IDs would be
The JNets user interfaceFigure 2
The JNets user interface. The main interface and network visualization panel from the JNets application is shown. JNets is 
displaying the HIV-1 human PPI network, from HHPID [6,7]. On the left is the legend panel showing the node and edge groups. 
The menu bar at the top is customizable. Standard drop-down menus can be enabled or disabled and new menus with user-
defined network views can be added, defined in the configuration file. On the right the subgroup edit and analysis panel is 
shown, through which the user can tailor the visualization, explore subgroup annotation and add further annotation to the net-
work.Page 3 of 14
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take different types of value; supported types are strings,
integers, decimal values (doubles) or boolean values (true
or false). Annotations are handled according to their class
and value type. This overall system of annotation allows
nodes and edges in JNets to be linked to a wide range of
data, biological or otherwise. Right clicking on a node or
edge allows an element information panel to be viewed.
These information panels display all the annotation that
has been loaded for any element, along with some basic
data such as the number of neighbors a node has, the ele-
ment identifier and label values.
Subgroup Creation
An integral feature of JNets is the ability to edit and inves-
tigate subgroups of elements. In the other network view-
ers, JSquid [13] and InterView [12], subgroups are
possible but are not dynamic, as they are predetermined
in the input file. However, in JNets, users can create novel
subgroups of elements using a simple, flexible system of
filtering element annotation. To create a subgroup, three
main components are considered. Firstly the input group.
This can be the whole network or a previously created
edge group, or node group. Note, the input group is the
set of elements that will be filtered. Secondly, the element
filter. There are two types of filter in JNets: automatic filters
and manual filters. Automatic filters create an array of sub-
groups by taking the input group and dividing elements
according to the value that they hold for a single annota-
tion. For example, in HHPID, proteins could be automat-
ically filtered according to their taxonomic identifier. This
would produce two subgroups of proteins: human and
HIV-1. Manual filters operate like SQL select statements,
where the input group is filtered according to any number
of constraints concatenated with AND and OR operators,
the output being elements that are true for that statement.
For example, the interactions in HHPID could be filtered
to find those that are annotated as binding OR activation
but NOT phosphorylation interactions. JNets also allows
nodes to be filtered according to edge annotation (and
vise versa) by taking in to account edge incidences at each
node. This greatly increases JNets flexibility in creating
subgroups. For example, by this method, human proteins
could be filtered according to whether they take part in an
interaction that is annotated as binding OR activation but
NOT phosphorylation. The third component is the output
type. This can be nodes, edges or both nodes and edges.
The output type determines the type of element that is
subject to regrouping. For example, HIV-1 proteins could
be filtered to find the HIV-1 accessory proteins Vpr and
Vpu. Given an output type of nodes and edges this would
result in the creation of a new node group consisting of
Vpr and Vpu and a new edge group of interactions involv-
ing Vpr and Vpu. Therefore, JNets allows users great free-
dom to create subgroups of interest. By creating and
visualizing network subgroups, patterns in the data (that
link network annotation and network structure) may
more easily be identified. Pattern identification may lead
to generation of hypotheses concerning the distribution
of annotation values over the network. These hypotheses
can be tested using the network analysis methods availa-
ble in JNets. The JNets subgroup creation interface is
shown in figure 3.
Network Analysis
JNets provides simple but powerful methods for analyz-
ing networks and the annotations that are attributed to
network elements. The main analytical capability in JNets
is to examine subgroups of elements and assess annota-
tion content using statistical methods. For example, using
only the HHPID data and JNets, it is possible to create a
subgroup of HIV-1-human interactions that involve the
Tat protein and discover that there are 774 such interac-
tions from a total of 2,588 unique PPIs.
Furthermore, the most statistically significant over-repre-
sented interaction type in this group is 'enhances', with a
total of 53 interactions (p = 3.3 × 10-15), using all interac-
tions as the general population, including a correction for
multiple tests. To produce such results, JNets will either
perform a two-tailed Fisher's Exact test, or Chi-Square
approximation test, depending on the population size.
The hypergeometric and chi-squared distributions
required to do these tests are calculated using classes from
the open source Colt 1.2.0 Java package. Where appropri-
ate, correction for multiple significance testing is imple-
mented automatically, using the Benjamini-Hochberg
false discovery rate method [15].
This system of analysis allows JNets to remain both flexi-
ble (as both the annotation and the subgrouping used in
the analysis are determined entirely by the user) and fast
(as these calculations are computationally simple), partic-
ularly important for deployment as an applet. Further-
more, as calculations are performed directly upon visible
subgroups of the network, a link between the visual and
statistical output of JNets is explicit. The following case
study demonstrates the power of these analysis methods.
Network Manipulation
A key feature of JNets is the ability to manipulate the net-
work to improve visualizations. Basic but very useful
manipulations available in JNets include setting node and
edge colors, setting node sizes, turning node labels on or
off, collapsing parts of the network to form composite
nodes, deleting elements and sticking nodes to prevent
the spring layout from acting upon them. Most of these
features were previously available in InterView, but acted
upon the entire network only. With JNets, these actions
can also be applied to novel subgroups of nodes or edges,
created by filtering network annotation, to tailor the visu-
alization to the requirements of the user.Page 4 of 14
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The JNets subgroup creation interfaceFigure 3
The JNets subgroup creation interface. This interface is used to create a new subgroups from already existing ones. The 
upper half of this panel is used to select some simple options about the subgroups being created, such as whether the grouping 
should be made automatically or manually, what the name of new subgroups should be and whether new a new node group, 
edge group, or both should be created. The lower half of this panel is used to select the annotation and set the filters through 
which new subgroups will be created.
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JNets can also be customized by providing a configuration
file. The configuration file is also in XML format. There are
three main aspects of JNets configuration. Firstly, simple
user-interface customization. Much of the user interface
can be disabled including drop-down menus and right-
click functions and the legend panel can be hidden or
shown. The ability to create novel subgroups of elements
can be disabled, as can specific parts of the subgroup edit
and analysis panel. Secondly, the configuration file can
determine what data JNets will use from the input
XGMML file, in terms of nodes, edges and annotations.
This configuration feature allows a single input file to be
used, with a number of configurations, to produce a
number of different networks. Thirdly, and most impor-
tantly, preset network views can be determined in the con-
figuration file. Network views are defined in the
configuration file as sets of annotation filters that encode
the creation of new node and edge subgroups in the net-
work. These presets allow groups of nodes and edges to be
hidden, so that specific parts of the network can be high-
lighted. The presets appear in new drop down menus on
the main menu bar and on a mouse click will execute the
filters to alter the network view.
Case study: Drug targets in the HIV-host network
To demonstrate the utility of JNets as a network visualiza-
tion and analysis tool, human genes that code for prod-
ucts that are both HIV-1 interacting and approved drug
targets were examined, using HHPID as a source for HIV-
1-host interactions.
Case study: Introduction
To date, only one U.S. Food and Drug Administration
(FDA) approved therapeutic agent, maraviroc, developed
by Pfizer, directly targets a host, rather than a viral protein
in the treatment of HIV-1 infection. Maraviroc is an antag-
onist of the CCR5 chemokine receptor and prevents
CCR5-tropic strains of HIV-1 from binding this co-recep-
tor and entering host immune cells [16]. Other HIV-1
therapeutic agents may follow the lead of maraviroc and
target host, rather than viral proteins, in the treatment of
HIV-1 infection. For example, HMG-CoA reductase inhib-
itors (statins) are normally used to treat high cholesterol
but have been shown to increase CD4+ cell counts and
decrease viral load in HIV-1 infected patients. This action
is thought to be due to the negative regulation of Rho
GTPase activity by statins, impeding viral entry and bud-
ding from the cell [17], further evidence that targeting
host proteins can disrupt HIV's biology. It is also possible
to target HIV-host interactions directly. For example, dis-
rupting the Vif-APOBEC interaction with a small-mole-
cule, RN-18, is a strategy that is currently being pursued
[18] because Vif mediates the degradation of the potent
anti-retroviral APOBEC proteins (see review [19]) and in
the absence of Vif, HIV-1 virions are non-infective [20].
In this case study we use JNets to explore the HIV-1-inter-
acting proteins that are approved drug targets, as this may
provide a useful insight for researchers investigating new
therapeutic strategies to treat HIV-1 infection and, at the
very least, indicate that a human protein that HIV interacts
with is to some extent "druggable". Moreover, close exam-
ination of the drug classes and drug targets in this intersect
may highlight ways that HIV-1 acts to perturb the host sys-
tem. We consider both the details of the HIV-1 interac-
tions and the types of drugs that target these human
proteins.
Case study: Methods
HHPID data were downloaded from the National Centre
for Biotechnology Information (NCBI) on May 1st, 2008.
These data included the update to HHPID that includes
Env gene-product interactions (available November 13th,
2007). The HIV-1 interaction type was taken from the
'interaction' column of this data file. FDA approved drug
and drug-target information was taken from the down-
loadable file 'drugcard set.txt' from the DrugBank data-
base [21,22] on June 3rd, 2008. Drug categories were
extracted from the 'Drug_Category' field and the Anatom-
ical Therapeutic Chemical (ATC) classification system
code was taken from the 'ATC_Codes' field of the same
file.
A single HIV-1-host, drug-target network was created to
conduct the investigation. The nodes in this network con-
sisted of all FDA-approved drugs and all FDA-approved
drug-target genes, all human genes that code for an HIV-
interacting product and all HIV-1 elements (the term 'ele-
ments' is used because some of these are genes and pro-
teins). Genes present both in the drug-target and HIV-1
interacting groups were only represented by a single node.
There were two types of edges in this network: HIV-host
interactions and drug-target interactions. HIV-host inter-
actions came from HHPID. There were 3,939 distinct
interactions between the nodes of HIV-1 and the host, dis-
tinct on the HIV-1 element, the host gene and the interac-
tion type. Therefore by this definition, interactions that
are reported in multiple source articles only count as one
interaction. However, multiple interactions between the
same nodes are possible as these may have significantly
different interaction types, e.g., 'upregulates' and 'down-
regulates'. The nodes in the network were annotated,
where relevant, with drug classifications and ATC codes,
the number of distinct HIV-1 interactors and the number
of HIV-1 interactions. The edges in the network were also
annotated where relevant, with information derived from
HHPID, such as the interaction type and whether the
interaction is agonistic, antagonistic or neither.
All results were produced by visualizing and analyzing
the HIV-1-host, drug-target network using the JNets appli-
cation.Page 6 of 14
(page number not for citation purposes)
BMC Bioinformatics 2009, 10:95 http://www.biomedcentral.com/1471-2105/10/95Case study: Results
The HIV-1-host, drug-target interaction network con-
tained 3,492 nodes and 7,374 edges. Of the nodes, 19
were HIV-1 elements, 2,391 were human genes and 1,082
were drugs. Of the 2,391 human genes, 1,434 coded for
HIV interacting products, 1,194 coded for approved drug
targets and 237 coded for products that were both HIV-1
interacting and drug targets (throughout, we will refer to
this gene set as HIDTs). HIDTs account for 17% of human
genes that code for HIV-1 interacting products and 20% of
the genes that code for drug targets. Of these 237 genes,
we found gene-products of 178 to have one or more direct
physical interactions with HIV-1, based upon the interac-
tion type. This network also contained 7,374 edges: 3,939
HIV-host interactions and 3,435 drug-target interactions.
The whole HIV-1-host, drug-target interaction network is
displayed in figure 4, where HIDTs are highlighted. A sec-
ond network view is shown in figure 5 in which JNets has
been used to filter the network to show HIV-1 interactions
with HIDTs. From this visualization, it is clear that many
HIDTs interact with multiple HIV-1 elements and that cer-
tain HIV-1 elements (such as Env-gp120) are responsible
for many more HIV-HIDT interactions than others (such
as the p6 protein). These aspects of the network were
investigated in more detail using JNets.
Of the 237 HIDTs, the gene-products from 114 interact
with more than one distinct HIV-1 element. Using JNets,
we showed that this is significantly greater than expected
(Fisher's exact test, p < 0.001), given that from 1,434
human genes whose products are HIV-1 interacting, 529
have interactions with more than one distinct HIV-1
The HIV-1-host, drug-target interaction networkFigure 4
The HIV-1-host, drug-target interaction network. This is the whole network that was used for all analyses in our case 
study. Using the annotation that accompanies nodes and edges, JNets can filter this network to create more focussed visualiza-
tions, for example, the networks in figures 5-7.
HIV-1 element
FDA approved drug
HIV-1 interacting human gene
Drug target human gene
HIV-1 interacting, drug target human gene
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targeted by more than one drug. By performing a Fisher's
exact test on the drug-target network, we showed that this
is a significantly greater proportion than expected at ran-
dom (p < 0.001), given that 1,194 approved drug-target
genes were identified in DrugBank and only 501 of these
are targeted by more than one drug.
From 3,939 HIV-host interactions, 820 are between HIV-
1 and HIDTs. We examined the HIV-1 elements that are
responsible for these 820 interactions. We found signifi-
cantly more Env-gp120 and Env-gp41 interactions and
significantly fewer Tat and Integrase and Rev interactions
among drug target genes, than would be expected, given
the 3,939 HIV-human interactions as a parent population.
See Table 1 for more details.
Next, we examined the drugs that target the products of
HIV-1-Interacting-DTs, compared to other drug target
genes in the human genome. We found that drugs from
HIV-1 interacting drug target genesFigure 5
HIV-1 interacting drug target genes. This network shows 237 human genes that encode products that are HIV-1 interact-
ing and FDA-approved drug targets. HIV-1 elements are labelled. Human genes are colored according to the number of distinct 
HIV-1 elements with which they share an interaction (darker = more). The layout of this network was achieved by manually 
positioning the HIV-1 nodes, locking them in position and allowing the JNets spring layout to reposition the remaining human 
gene nodes. As a result, human gene nodes with multiple interactors are drawn to the centre of the network. From this visual-
ization it is clear that many HIDTs interact with multiple HIV-1 elements and that certain HIV-1 elements are responsible for 
many more HIV-HIDT interactions than others. Such observations can be investigated in greater detail using JNets. For exam-
ple, 114 from 237 of these human genes interact with more than one HIV-1 element. This is significantly more than would be 
expected at random (p < 0.001).
InteractionPage 8 of 14
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tions denoted in DrugBank, are more likely to target
gene products of HIDTs than would be expected at ran-
dom, given all human drug target genes in DrugBank as a
parent population. In total, we identified six such classes
that showed over-representation (p < 0.001, table 2). We
investigated three particular over-represented groups of
genes in greater detail: (i) HIDTs that code for gene-prod-
ucts targeted by immunosuppressive agents, this was the
most overrepresented drug category (p = 1.87 × 10-13), (ii)
HIDTs that code for gene products targeted by antineo-
plastic agents, the second most over-represented category
(p = 7.87 × 10-9), and (iii) HIDTs that code for gene-prod-
ucts targeted by statins – a specific subset of the category
'lipid modifying agents'. To identify as many HIDTs as
possible whose products are targeted by these three drug
types, we widened our search to take into account level-2
ATC codes and drug classifications from DrugBank.
Immunosuppressants were defined with drug classifica-
tion 'immunosuppressive agents', or, with the corre-
sponding ATC level-2 classification 'L04'. Antineoplastic
agents were defined with a drug classification containing
the word 'antineoplastic', or, with the corresponding ATC
level-2 classification 'L01'. Statins were defined with a
drug classification of 'HMG CoA reductase inhibitors' or
'Hydroxymethylglutaryl-CoA Reductase Inhibitors', or,
one of the level-3 ATC classifiers: 'C10AA' (HMG CoA
reductase inhibitors), 'C10BA' (HMG CoA reductase
inhibitors in combination with other lipid modifying
agents) or 'C10BX' (HMG CoA reductase inhibitors, other
combinations). After this redefinition, all three chosen
drug groups were still statistically over-represented among
drugs targeting the products of HIDTs, compared to other
human drug target genes (p < 0.001).
We found 21 HIDTs whose gene products are a target for
HMG-CoA reductase inhibitors. This is 66% of all statin
target genes given in DrugBank. This group shows a rela-
tively high degree in the HIV-1-host network; the average
degree of a host node is 2.8 but for this group of nodes the
average degree was 6.7. From these 21 genes, 13 code for
products that interact with Nef (over-represented where p
< 0.001), 15 with Env gp120 and five with the Matrix pro-
tein (both over-represented where p < 0.05). In addition,
these 21 HIDTs have certain over-represented interaction
types with HIV-1 (p < 0.05): HIV-1 is activated by three,
induces the release of five and upregulates the gene-prod-
ucts of 12 HIDTs in this group. Among these 21 HIDTs
were the HMG-CoA reductase gene, whose gene-product
is modulated by Nef and the ras homolog, member A
(RhoA), whose gene-product is upregulated by Vpr and
activated by Tat.
Table 1: HIV-1 interactions with approved drug target genes, by HIV-1 element.
HIV-1 element Total interactions Interactions with drug target genes Corrected p
Env-gp120 856 (22%) 239 (29%) 5.85 × 10-6
Integrase 102 (3%) 5 (1%) 7.15 × 10-4
Rev 109 (3%) 7 (1%) 1.36 × 10-3
Env-gp41 190 (5%) 58 (7%) 4.65 × 10-3
Tat 1394 (35%) 249 (30%) 2.50 × 10-2
Capsid 45 (1%) 16 (2%) 6.23 × 10-2
Vif 77 (2%) 8 (1%) 6.57 × 10-2
Nef 302 (8%) 78 (10%) 7.60 × 10-2
Pol 1 (< 1%) 0 (0%) 0.238
Vpr 275 (7%) 47 (6%) 0.173
Env-gp160 213 (5%) 49 (6%) 0.432
Env-gp41 190 (5%) 58 (7%) 1.07 × 10-2
Rev 109 (3%) 7 (1%) 4.50 × 10-3
Integrase 102 (3%) 5 (1%) 2.61 × 10-3
Matrix 95 (2%) 15 (2%) 0.399
Retropepsin 89 (2%) 15 (2%) 0.506
Vif 77 (2%) 8 (1%) 0.120
Gag 72 (2%) 15 (2%) 0.889
Reverse transcriptase 45 (1%) 8 (1%) 0.605
Vpu 27 (1%) 5 (1%) 0.667
Nucleocapsid 26 (1%) 4 (< 1%) 0.486
p6 18 (< 1%) 2 (< 1%) 0.386
p1 3 (< 1%) 0 (0%) 0.253
The proportion of interactions that HIV-1 has with the products of genes that also encode drug targets, compared to total interactions, grouped by 
HIV-1 element are shown. The statistical significance of the difference in expected and actual figures, indicated by p-values, were calculated in JNets 
using two-tailed Chi-square tests, corrected for multiple testing using the Benjamini and Hochberg method [15]. Using a p cutoff of 0.05, we found 
significantly more Env-gp120 and Env-gp41 interactions and significantly fewer Tat, Integrase and Rev interactions among drug target genes, than 
would be expected at random.Page 9 of 14
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81 different antineoplastic agents. This is 43% of all anti-
neoplastic agent target genes given in DrugBank. From
these 73 genes, the notable HIV-1 elements that their
gene-products interact with are Env-gp120 (41 genes) and
Nef (23 genes), which are over-represented (p < 0.05).
From this group, no particular HIV interaction type was
found to be statistically over-represented, after correcting
for multiple tests. However, the most abundant classes
were 'interacts with' (25 genes), upregulates (24 genes),
activates (21 genes), inhibits (19 genes), binds (19 genes)
and downregulates (12 genes). The 81 antineopastic
agents that target the gene-products of HIV-1-Interacting-
DTs were from a wide range of ATC classifications. From
those with level 2 ATC class 'L01', corresponding specifi-
cally to antineoplastic agents, the most abundant were
drugs from the 'L01X' level 3 ATC class, corresponding to
'other antineoplastic agents'. Therefore, a specific group of
antineoplastic agents that target the same gene-products
as HIV-1, was not easily identifiable.
Given the nature of HIV-1 infection, the immune cells
that become infected and the detrimental effect that this
infection can have on the immune response of the host,
we expect to see a high proportion of immune system pro-
teins among HIV-1 interacting drug targets. Indeed we
found 35 genes in HHPID whose products are a target for
immunosuppressants. This is 63% of all immunosuppres-
sant target genes given in DrugBank. From these 35, the
outstanding HIV-1 elements that they interact with, as for
antineoplastic agent target genes, are Env-gp120 (25
genes) and Nef (15 genes), which are over-represented (p
< 0.001). However, the products of these genes also inter-
act with Env-gp41, 10 genes, and the capsid protein, four
genes (p < 0.05). From this group of 35 genes, HIV-1 acts
to downregulate the products of 16 (over-represented, p <
0.001). This was the only statistically significant HIV-1
interaction type detectable among this group of genes
after correcting for multiple tests. However, HIV-1 also
inhibits 12, upregulates 15 and activates the products of
five genes from this group. Figure 6 shows the drug-target
network, filtered to show only HIV-1-interacting immu-
nosuppressant target genes, the immunosuppressive
drugs and the HIV-1 elements that target the products of
these genes. The human genes are colored according to the
general action that HIV-1 infection has upon their prod-
ucts. Three categories are defined: agonised (e.g., activate,
upregulate and enhance), antagonised (e.g., inhibit,
downregulate and degrade), both agonised and antago-
nised, or neutral/unspecified (e.g., binds, modulates and
interacts with). The agonised group contained 7 genes, the
antagonised 11 genes, the agonised and antagonised 12
genes and five neutral genes, respectively. We found 25
immunosuppressive drugs that target gene products that
are HIV-1 interacting, 18 of these drugs have more than
one such target. The majority (14) of these 25 drugs have
a level 4 ATC classification 'L04AA', meaning that they are
selective immunosuppressants. Figure 7 shows the same
results as in figure 6, however, for clarity, the drug nodes
and human genes from the neutral group have been
removed.
Case study: Discussion
As an example of the use of JNets, we have taken data from
HHPID and DrugBank to research the cross section of
genes that encode gene products that are both HIV-1 inter-
acting and drug targets. We have shown that a significant
proportion (237 genes, 17%) of genes that encode an
HIV-1-interacting product also encode an approved drug
target ('HIDTs'), of which 178 code for products that have
direct physical interactions with HIV-1. In addition, a sig-
nificant proportion of these interact with more than one
HIV-1 element. This suggests that products of these genes
are involved in important interactions with HIV-1, rather
than being incidental effects of HIV-1 infection. Thus,
drugging HIV-1 interacting proteins could potentially dis-
rupt the HIV-1 life cycle. These host proteins could be
explored in the search for new HIV-1 treatments.
Many of the HIV interactions involving HIDT gene prod-
ucts are with proteins from the Env complex, Nef and Tat.
Tat, the trans-activator of transcription, promotes viral
Table 2: HIV-1 interacting drug target genes by drug category. 
Level-2 ATC description Target genes HIV-1 interacting Corrected p
Immunosuppressive agents 36 (3%) 29 (12%) 1.87 × 10-13
Antineoplastic agents 100 (8%) 47 (20%) 7.87 × 10-9
Anti-inflammitory and antirheumatic products 27 (2%) 18 (8%) 3.03 × 10-6
Stomatological preparations 30 (3%) 19 (8%) 3.35 × 10-6
Lipid modifying agents 46 (4%) 23 (10%) 4.62 × 10-5
Antithrombotic agents 65 (5%) 29 (12%) 4.08 × 10-5
The proportion of drug target genes that encode HIV-1 interacting products, compared to the total number of drug target genes, grouped by the 
level-2 ATC categories of targeting drugs are shown. The statistical significance of the difference in expected and actual figures, indicated by p-
values, were calculated in JNets, using two-tailed Fisher's Exact tests, corrected for multiple testing using the Benjamini and Hochberg method [15]. 
We have only shown those categories where p < 0.001; all showed over-representation.Page 10 of 14
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induces operation of the host transcription machinery
and indirectly, the production of other viral proteins.
Therefore, as a result of some direct interactions, Tat is
also responsible for indirect, downstream responses in the
host cell, many of which will be more directly due to the
activity of transcription and the presence of other viral
proteins. Moreover, Tat interactions were actually under-
represented among HIDTs. Therefore, it may not be Tat
interacting human proteins that are most interesting from
a drug-discovery perspective. In contrast, interactions with
the Env complex were found to be over-represented
among HIDTs. Env proteins and Nef are known to interact
with host proteins located in the membrane. For example,
the Envelope complex binds CD4 receptors and several
co-receptors including CCR5 [24]. Nef, or negative factor,
is known to downregulate CD4 [25] and class I MHC mol-
ecules [26]. Around 70% of drugs are believed to target
membrane proteins [27], which may explain the promi-
nance of Nef and Env interacting drug targets and the
over-representation of Env interacting drug targets in our
network.
Using JNets, we have shown that human genes that code
for products targeted by HMG-CoA reductase inhibitors,
antineoplastic agents and immunosupressive agents are
over-represented in the HIV interaction data. HIV-1 inter-
acts with the majority of targets of HMG-CoA reductase
inhibitors, including HMG-CoA reductase itself. The HIV-
1 virion requires clustering of host lipid 'rafts', also known
as DIGs (detergent-insoluble glyco-lipid-enriched micro-
domains), for entry to and budding from the host cell
[17]. Raft formation is believed to be controlled by Rho
GTPases and remodelling of the actin cytoskeleton. HMG-
CoA reductase is required to prenylate and activate these
GTPases. Nef is thought to associate with these rafts and
prime T-cells for activation and may promote HIV-1 repli-
cation [28]. However, due to the extensive crossover we
have observed between the targets of HMG-CoA reductase
inhibitor and HIV-1 interacting proteins, it seems likely
that other mechanisms are active that give HMG-CoA
reductase inhibitors the ability to decrease viral load in
infected patients. One indicator of this is that the HMG-
CoA inhibitor target genes have a particularly high degree
in the HIV-1-host protein interaction network, suggesting
that they are particularly important in the HIV-1 life cycle.
Env-gp120 has interactions with the products of 15 of
these genes, which is unsurprising when we consider that
Env associates with many host membrane proteins and
that these 15 host genes are likely to be involved in mem-
brane raft formation and HIV-1 entry and exit from the
cell. One notable interaction that Env has with a host pro-
tein is with coagulation factor II (thrombin). Thrombin
has been shown to activate the Env complex and enhance
fusion of the virus to the host cell [29]. Thrombin is also
a target to the HMG-CoA reductase inhibitor simvastatin
Drug-target network showing all immunosuppressant target HIV-1 interacting genesFigure 6
Drug-target network showing all immunosuppressant target HIV-1 interacting genes. The drug nodes lie in an arc 
around the top of the network. Between these two groups are the human gene nodes, colored according to the action HIV-1 
has upon them. Four types of action are defined: agonised [7], antagonised [11], agonised and antagonised [12] and neutral/
unspecified [5]. These distinctions are derived from the interaction description supplied with each HHPID HIV-1-host interac-
tion. HIV-1 elements are shown at the bottom and are labelled. The human genes shown in this network are likely to perform 
a significant role in the immune system to be targeted by immunosuppressive drugs. From this visualization it is clear that HIV-
1 targets many of the same proteins as immunosuppressant drugs.
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Interaction
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Antagonized
Agonized and antagonized
Neutral/unspecificPage 11 of 14
(page number not for citation purposes)
BMC Bioinformatics 2009, 10:95 http://www.biomedcentral.com/1471-2105/10/95– a possible mechanism through which statins may be
effective drugs in the treatment of HIV-1 infection.
From our results it is not clear why antineoplastic agents
and HIV-1 share many human targets. By manually exam-
ining the group of drugs that target the products of these
genes, it was noted that many are monoclonal antibodies,
such as Trastuzumab (commonly known as Herceptin),
that bind cell surface receptors. Trastuzumab action is
believed to be involved with the mitogen-activated pro-
tein kinase (MAPK) cascade [30], a pathway with which
HIV-1 infection is also highly associated, for example, the
MAPK-1 gene has 22 distinct interactions with HIV-1 in
our network, with 10 distinct HIV-1 elements. The sys-
temic effects of antineoplastic agents and of HIV-1 infec-
tion may utilise many of the same intrinsic cellular
pathways. AIDs-related malignancies are not an uncom-
mon cause of death for HIV-1 infected patients [31,32].
This suggests that research in to the use of antineoplastic
therapies in HIV-1 infected patients, may benefit from
greater utilization of network-based approaches. Such
approaches may lead to improved treatment strategies
that avoid provoking greater levels of infection and virus-
induced host cell perturbation. For example, to better
understand crossover in specific cellular pathways, host
proteins could be annotated with pathway data, points of
contact with viral proteins, and drugs could then be iden-
tified and the network analysed further using JNets.
Our analysis has shown that the majority of the targets of
immunosuppressive drugs are also HIV-1 interacting, an
observation that we have shown to be statistically signifi-
cant. In the case of HIV-1 infection, interaction with ele-
ments from the host immune response is particularly
likely, as HIV infects cells that are specific to this host sys-
tem, such as T-cells and macrophages. Therefore, HIV-1
requires a sufficient host immune response so that it has
cells to infect but may also downregulate elements of the
HIV-1 host network showing immunosuppressive agent target genesFigure 7
HIV-1 host network showing immunosuppressive agent target genes. Human genes that are both HIV-1 interacting 
and targeted by immunosuppressive agents are shown. Only those genes that are explicitly agonised or antagonised by HIV-1 
have been included; human genes are colored according to this action. Seven host genes are agonised, eleven are antagonised 
and twelve are both agonised and antagonised. These distinctions are derived from the interaction description supplied with 
each HHPID HIV-1-host interaction.
Agonized
Agonized and antagonized
Antagonized
Agonistic interaction
Antagonistic interaction
Agonistic and antagonistic interactionsPage 12 of 14
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order to evade other aspects of the immune system. This
complexity is exemplified in our results, particularly in the
network visualizations shown in figures 6 and 7. Figure 7
shows that HIV-1 elements, particularly Nef, Tat and Env,
act to both agonise and antagonise proteins that are
intrinsic to the host immune response. For example, there
is no clear relationship that defines HIV-1 action on inter-
leukin receptors (i.e., IL2RA, IL1RA, IL2RB). This could be
due to a single, static network view being insufficient to
expose variable aspects of HIV-1 infection, such as the
point in the cell-cycle, the stage of HIV-1 infection and the
infected cell type – it is inconceivable that these interac-
tions all occur simultaneously in a single cell. Even so, this
representation does suggest that HIV-1 possesses an intri-
cate system for influencing the host immune response
that is necessary to maintain the infection.
Conclusion
In our case study, we have integrated data from DrugBank
and HHPID to perform analyses. We have demonstrated
that JNets is capable of combining biological annotation
and interaction network data to allow specific visualiza-
tions to be created and statistical conclusions to be drawn,
from which biological inferences can be made. However,
JNets is not designed to compete with heavily developed
network analysis packages, such as Cytoscape [8] and
Pathway Studio [9]. These applications incorporate a
plethora of functions for the analysis of biological net-
works. A drawback of such applications is that the utilities
on offer may fall beyond the scope of many users, as add-
ing greater functionality to software can complicate user
interfaces and make simple tasks less accessible. Rather,
JNets is designed to allow network visualization and some
useful analysis to be carried out in a simple, web-deploy-
able tool. By this system, vendors could use JNets as a
'gateway' to allow users to interact with, and better under-
stand network data.
No part of JNets is specific to biological networks, making
JNets useful across a wide range of disciplines. JNets is
also configurable, to allow preset network views and sub-
divisions of networks to be stored. This aspect of the
applet makes use of the JNets annotation filtering
method, so that very different visualizations can be ren-
dered from a single input file, available to the user at a
mouse click. Much of the JNets system is based around the
dynamic creation of subgroups by filtering network anno-
tation. By offering these features, JNets is quite different
from any other web deployable network visualization tool
that is currently available. For example, WebInterViewer is
designed to render a large number of nodes with great effi-
ciency, although annotation can accompany the network
[11]. VisAnt [10] analysis focusses on graph-theoretical
properties and integration of annotation from predeter-
mined sources. JSquid [13] was primarily designed as an
interactive viewer for the FunCoup website http://fun
coup.sbc.su.se, though it can be used for viewing inde-
pendent network data. JSquid also makes use of node and
edge groupings, however, unlike JNets, will not perform
analyses on user defined features of these groups.
In summary, JNets is a platform independent, interactive
network visualization and analysis tool, suitable for a
wide range of network data and capable of being deployed
from a website as a customized applet or run as a stand-
alone application. For further information about JNets
please visit http://www.manchester.ac.uk/bioinformatics/
jnets.
Availability and requirements
• Project name: JNets
• Project home page: http://www.manchester.ac.uk/
bioinformatics/jnets
• Operating system(s): Platform independent
• Programming language: Java
• Other requirements: Java 1.5 or higher
• License: GNU GPL
• Any restrictions to use by non-academics: No
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